SCHEMBL16185156

SCHEMBL16185156

CCOc1cc(-c2cc(F)ccc2F)cc2c(NC)nc(-c3ccncn3)nc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 2/20 0.38
▸ SCN9A Q15858 1/20 0.36
▸ POLB P06746 1/20 0.34
▸ EGFR P00533 5/20 0.33
▸ LMNA P02545 3/20 0.33
▸ MAPT P10636 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ CASP6 P55212 1/20 0.32
▸ GRM5 P41594 2/20 0.32
▸ ERBB2 P04626 2/20 0.32
▸ MAP4K4 O95819 1/20 0.32
▸ FRK P42685 1/20 0.32
▸ MAPK9 P45984 1/20 0.32
▸ CSNK1A1 P48729 1/20 0.32
▸ CDK9 P50750 1/20 0.32
▸ LATS1 O95835 1/20 0.32
▸ MAP3K11 Q16584 1/20 0.31
▸ NAMPT P43490 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16185149 0.93 CHRNA7 (0.38) CHRNA7SCN9APOLBEGFRLMNA
SCHEMBL16185152 0.91 SCN9A (0.42) SCN9ALMNAMAPTSMN1; SMN2CDK9
SCHEMBL14475269 0.90 KDM4E (0.35) CHRNA7SCN9APOLBEGFRLMNA
SCHEMBL16185142 0.90 CHRNA7 (0.42) CHRNA7SCN9AEGFRLMNAMAPT
SCHEMBL16185154 0.88 GRM5 (0.42) CHRNA7LMNASMN1; SMN2GRM5KDM4E
SCHEMBL16185166 0.88 CHRNA7 (0.36) CHRNA7SCN9AEGFRLMNAMAPT
SCHEMBL16185157 0.87 CHRNA7 (0.39) CHRNA7POLBLMNAMAPTCASP6
SCHEMBL16185160 0.87 GRM5 (0.40) CHRNA7POLBEGFRLMNAMAPT
SCHEMBL14474686 0.86 SCN9A (0.37) CHRNA7SCN9AEGFRLMNASMN1; SMN2
SCHEMBL14474191 0.86 GRM5 (0.44) CHRNA7SCN9AEGFRLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB CHRNA7 349/4885SCN9A 3217/4885POLB 2309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback